Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase
- 1 November 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (21) , 5389-5394
- https://doi.org/10.1016/j.bmcl.2004.08.007
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Protein kinase activation and myocardial ischemia/reperfusion injuryCardiovascular Research, 2004
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- Pyridinylimidazole based p38 MAP kinase inhibitors.Current Topics in Medicinal Chemistry, 2002
- The Non-Diaryl Heterocycle Classes of p38 MAP Kinase InhibitorsCurrent Topics in Medicinal Chemistry, 2002
- Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical CandidateJournal of Medicinal Chemistry, 2002
- New inhibitors of p38 kinaseExpert Opinion on Therapeutic Patents, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- p38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic PotentialsPharmacology & Therapeutics, 1999
- EtanerceptDrugs, 1999
- A protein kinase involved in the regulation of inflammatory cytokine biosynthesisNature, 1994